Latest From ChemoCentryx Inc.
Public Company Edition: At the J.P. Morgan Healthcare Conference and Biotech Showcase it was noted that the US IPO market is likely to be less active in the second half of the year as election risk chills investment. Also, Apellis leads recent follow-on offerings.
The company and partner Vifor said the selective complement 5a receptor inhibitor met both primary and multiple secondary endpoints; US and EU filings are planned for 2020.
Switzerland’s leader in iron deficiency therapies wants to add new products in this and adjacent therapeutic areas, as strong revenue growth in 2018 backs its strategy of concentrating its efforts on the pharmaceuticals business.
ChemoCentryx and Vifor Fresenius have changed their conditional marketing authorization application for avacopan to a full MAA in the EU after it emerged that data from the ADVOCATE study will be more comprehensive than expected.
- Drug Discovery Tools
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Renal System
- North America
- Parent & Subsidiaries
- ChemoCentryx Inc.
- Senior Management
Thomas J Schall, PhD, Pres. & CEO
Susan M Kanaya, EVP, CFO & Chief Administrative Officer
Markus J Cappel, PhD, CBO
William Fairey, EVP, COO
- Contact Info
Phone: (650) 210-2900
850 Maude Ave.
Mountain View, CA 94043
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.